Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Launxp Biomedical CoROCO:6876 -1.62%11 Buyback Yield % is -20.88 as of Jul. 22, 2026. GuruFocus rates ROCO:6876 with a GF Score™ of 11/100. The stock has 4 warning signs investors should review. Among 740 Biotechnology companies, Launxp Biomedical Co ranks worse than 67.7% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Launxp Biomedical Co Buyback Yield % Related Terms
Launxp Biomedical Co Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Launxp Biomedical Co's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6876 vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, Launxp Biomedical Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Launxp Biomedical Co Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Launxp Biomedical Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Launxp Biomedical Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Launxp Biomedical Co (ROCO:6876) has a Buyback Yield % of -20.88 as of Jul. 22, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Launxp Biomedical Co and its competitors. According to the industry distribution chart, Launxp Biomedical Co ranks #501 out of 740 companies in the Biotechnology industry, placing it in the top 67.7%.
Is Launxp Biomedical Co's Buyback Yield % too high?
Launxp Biomedical Co's current Buyback Yield % is -20.88. Based on the distribution chart, Launxp Biomedical Co ranks #501 out of 740 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Launxp Biomedical Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Launxp Biomedical Co's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Launxp Biomedical Co ranks #501 out of 740 companies for Buyback Yield %. This places Launxp Biomedical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Launxp Biomedical Co and its competitors. Launxp Biomedical Co's current Buyback Yield % is -20.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Launxp Biomedical Co stock overvalued right now?
Launxp Biomedical Co (ROCO:6876) has a current Buyback Yield % of -20.88. The current Buyback Yield % is -20.88. Launxp Biomedical Co's overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Launxp Biomedical Co (ROCO:6876), the current Buyback Yield % is -20.88 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Launxp Biomedical Co Ltd is a company that researches, designs and develops Cancer drug rapid screening platform and Early development evaluation and technology licensing of generic drugs for cancer treatment. The company mainly focuses on the screening of development drugs, formulation of development strategies, project management, planning and execution of regulations and clinical trials, etc.
11GF Score
Get the complete analysis for ROCO:6876
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6876 has been successfully added to your 
